TG Therapeutics, Inc. (LON:0VGI)
London
· Delayed Price · Currency is GBP · Price in USD 37.50
-1.05 (-2.72%)
At close: Mar 14, 2025
TG Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | - | 179.89 | 92.93 | 102.3 | 298.89 | 553.44 | Upgrade
|
| Short-Term Investments | - | 131.11 | 124.58 | 59.37 | 15.88 | 51.99 | Upgrade
|
| Cash & Short-Term Investments | 311 | 311 | 217.51 | 161.68 | 314.76 | 605.43 | Upgrade
|
| Cash Growth | 48.25% | 42.98% | 34.53% | -48.63% | -48.01% | 331.11% | Upgrade
|
| Accounts Receivable | - | 129.19 | 51.09 | - | 1.39 | - | Upgrade
|
| Receivables | - | 129.19 | 51.09 | - | 1.39 | - | Upgrade
|
| Inventory | - | 110.46 | 39.82 | - | - | - | Upgrade
|
| Other Current Assets | - | 15.72 | 9.52 | 6.6 | 14.81 | 6.31 | Upgrade
|
| Total Current Assets | - | 566.36 | 317.94 | 168.27 | 330.97 | 611.74 | Upgrade
|
| Property, Plant & Equipment | - | 7.15 | 8.05 | 9.2 | 9.23 | 9.79 | Upgrade
|
| Long-Term Investments | - | 0.81 | - | 12.4 | 35.53 | - | Upgrade
|
| Goodwill | - | - | - | 0.8 | 0.8 | 0.8 | Upgrade
|
| Long-Term Deferred Charges | - | - | - | 1.63 | 1.84 | 2.05 | Upgrade
|
| Other Long-Term Assets | - | 3.37 | 3.59 | 1.27 | 1.26 | 1.26 | Upgrade
|
| Total Assets | - | 577.69 | 329.59 | 193.57 | 379.63 | 625.64 | Upgrade
|
| Accounts Payable | - | 26.3 | 29.27 | 42.02 | 50.89 | 37.01 | Upgrade
|
| Accrued Expenses | - | 15.19 | 12.17 | 8.43 | 10.17 | 8.46 | Upgrade
|
| Current Portion of Long-Term Debt | - | 0.66 | 0.36 | 0.24 | 1.34 | 23.12 | Upgrade
|
| Current Portion of Leases | - | 1.16 | 1.45 | 1.58 | 1.44 | 1.67 | Upgrade
|
| Current Unearned Revenue | - | 11.41 | 0.15 | - | 0.2 | 0.2 | Upgrade
|
| Other Current Liabilities | - | 35.97 | 10.32 | 0.93 | 1.35 | 17.1 | Upgrade
|
| Total Current Liabilities | - | 90.68 | 53.72 | 53.2 | 65.38 | 87.55 | Upgrade
|
| Long-Term Debt | - | 244.43 | 100.12 | 71.14 | 66.79 | 7.72 | Upgrade
|
| Long-Term Leases | - | 8.13 | 9.23 | 10.34 | 9.85 | 10.41 | Upgrade
|
| Long-Term Unearned Revenue | - | 12.09 | 6.02 | 0.31 | 0.46 | 0.61 | Upgrade
|
| Total Liabilities | - | 355.33 | 169.09 | 134.99 | 142.48 | 106.29 | Upgrade
|
| Common Stock | - | 0.16 | 0.15 | 0.15 | 0.14 | 0.14 | Upgrade
|
| Additional Paid-In Capital | - | 1,760 | 1,713 | 1,586 | 1,566 | 1,500 | Upgrade
|
| Retained Earnings | - | -1,529 | -1,553 | -1,527 | -1,329 | -980.6 | Upgrade
|
| Treasury Stock | - | -8.99 | -0.23 | -0.23 | -0.23 | -0.23 | Upgrade
|
| Shareholders' Equity | 222.36 | 222.36 | 160.5 | 58.59 | 237.15 | 519.35 | Upgrade
|
| Total Liabilities & Equity | - | 577.69 | 329.59 | 193.57 | 379.63 | 625.64 | Upgrade
|
| Total Debt | 254.38 | 254.38 | 111.15 | 83.3 | 79.41 | 42.91 | Upgrade
|
| Net Cash (Debt) | 56.62 | 56.62 | 106.36 | 78.38 | 235.36 | 562.51 | Upgrade
|
| Net Cash Growth | -42.10% | -46.76% | 35.70% | -66.70% | -58.16% | 465.67% | Upgrade
|
| Net Cash Per Share | 0.34 | 0.35 | 0.72 | 0.58 | 1.78 | 4.88 | Upgrade
|
| Filing Date Shares Outstanding | 146.68 | 145.23 | 144.78 | 137.63 | 130.79 | 129.8 | Upgrade
|
| Total Common Shares Outstanding | 146.68 | 143.99 | 141.79 | 137.65 | 131.22 | 129.79 | Upgrade
|
| Working Capital | - | 475.68 | 264.22 | 115.07 | 265.58 | 524.19 | Upgrade
|
| Book Value Per Share | 1.54 | 1.54 | 1.13 | 0.43 | 1.81 | 4.00 | Upgrade
|
| Tangible Book Value | 222.36 | 222.36 | 160.5 | 57.79 | 236.35 | 518.55 | Upgrade
|
| Tangible Book Value Per Share | 1.54 | 1.54 | 1.13 | 0.42 | 1.80 | 4.00 | Upgrade
|
Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.